
Allopurinol
Allopurinol is the most widely used uric acid-lowering medicine. Trials show it brings more people to target uric acid than placebo, and it is approved for gout, cancer-treatment uric acid and certain kidney stones. Randomized trials found it did not prevent heart events in older adults with heart disease or slow kidney decline in chronic kidney disease, uses it is not approved for. Its key risks are rare but serious skin and hypersensitivity reactions. The critical interaction is with azathioprine.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with gout, people receiving cancer treatment that raises uric acid, and adults with recurrent calcium oxalate stones and high urine uric acid, whose prescriber recommends it
Common dosing range
Set by your prescriber: for gout, usually 100 mg a day to start, raised by 100 mg each week until blood uric acid is 6 mg/dL or less, up to 800 mg a day; lower in kidney disease
When to expect effects
Uric acid falls within weeks, but the label says gout control can take several months, and flares may increase at first
Watch out for
The label says to stop it and seek care at the first sign of a rash: rare severe skin reactions (SJS, TEN, DRESS) can be fatal, and risk is higher with the HLA-B*58:01 gene. No boxed warning. Critical interaction with azathioprine and mercaptopurine
What is it
Allopurinol is a prescription medicine that lowers uric acid. It is taken by mouth as generic allopurinol tablets (100 mg and 300 mg) or Zyloprim tablets; Aloprim is an injected form given in hospital to people with cancer who cannot take tablets. The tablet label approves it for gout, for high uric acid caused by cancer treatment, and for recurrent calcium oxalate kidney stones in adults with high uric acid in the urine. The label says it is not recommended for high uric acid without symptoms. This page is about the tablets.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
lowering blood uric acid in gout Good Evidence | Large on uric acid; fewer attacks not shown in short trials | Adults with chronic gout | Uric acid target measured at 30 days |
preventing heart attacks and strokes in heart disease without gout (not an approved use) Good Evidence | None | Not applicable; no benefit was found | Mean follow-up 4.8 years |
slowing chronic kidney disease without gout (not an approved use) Good Evidence | None | Not applicable; no benefit was found | Measured over 2 years |
lowering blood uric acid in gout
- Effect
- Large on uric acid; fewer attacks not shown in short trials
- Best fit
- Adults with chronic gout
- Time
- Uric acid target measured at 30 days
preventing heart attacks and strokes in heart disease without gout (not an approved use)
- Effect
- None
- Best fit
- Not applicable; no benefit was found
- Time
- Mean follow-up 4.8 years
slowing chronic kidney disease without gout (not an approved use)
- Effect
- None
- Best fit
- Not applicable; no benefit was found
- Time
- Measured over 2 years
Evidence for 3 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
lowering blood uric acid in gout
Biomarker supportA Cochrane review of 11 trials (4,531 people with chronic gout) treated allopurinol versus placebo as its main comparison. In one trial of 57 participants (moderate-quality evidence), 25 of 26 people on allopurinol 300 mg a day reached the target uric acid level over 30 days versus 0 of 25 on placebo. The same trial did not show fewer gout attacks over that short period (2 of 26 vs 3 of 25). Against febuxostat 80 mg a day, fewer people reached target uric acid on allopurinol 300 mg (38% vs 70%), with no clear difference in gout attacks.
Bottom line: Allopurinol brought more people to target uric acid than placebo; at 300 mg a day fewer reached target than with febuxostat 80 mg, and short trials were too small to show fewer gout attacks.
preventing heart attacks and strokes in heart disease without gout (not an approved use)
No benefit foundThis is not an approved use. In the open-label ALL-HEART trial, 5,721 people aged 60 or older with ischemic heart disease and no history of gout were randomized to allopurinol (up to 600 mg a day) or usual care and followed for a mean of 4.8 years. Heart attack, stroke or cardiovascular death occurred in 11.0% on allopurinol and 11.3% on usual care (hazard ratio 1.04), and deaths from any cause did not differ (10.1% vs 10.6%). Almost all participants (99.2%) were white.
Bottom line: Allopurinol did not lower heart attacks, strokes or deaths in older people with heart disease who did not have gout.
slowing chronic kidney disease without gout (not an approved use)
No benefit foundThis is not an approved use. In the CKD-FIX trial, 363 adults with stage 3 or 4 chronic kidney disease at high risk of progression and no history of gout took allopurinol 100 to 300 mg a day or placebo for 104 weeks. Kidney function (eGFR) fell by 3.33 mL/min/1.73 m2 per year on allopurinol and 3.23 on placebo, no significant difference. The trial stopped early for slow recruitment after enrolling 369 of 620 planned patients.
Bottom line: Allopurinol did not slow kidney function decline in people with chronic kidney disease who did not have gout.
How it works
How to take it
What to track
Bottom line: Your prescriber sets and adjusts the dose to your uric acid level; the label says to take it after a meal with plenty of fluid, and to stop it and seek care at the first rash.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Serious and sometimes fatal skin and hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, in about 5 in 10,000 people (0.05%), mostly in the first few months. The risk is higher with the HLA-B*58:01 gene, more common in people of African, Asian (for example Han Chinese, Korean, Thai) and Native Hawaiian or Pacific Islander ancestry. The label says to stop allopurinol permanently at the first sign of a rash. The current label has no boxed warning.
Kidney injury from xanthine stones or urate deposits, with higher risk in existing kidney disease or a history of stones; the label advises enough fluid for at least 2 liters of urine a day.
Liver injury (usually reversible) and low blood counts (anemia, low white cells or platelets), which have occurred from 6 weeks to 6 years after starting.
Who should avoid it
- People with a history of hypersensitivity to allopurinol (contraindicated)
- People who carry HLA-B*58:01 (not recommended unless benefits clearly outweigh risks)
- People with high uric acid but no symptoms (not recommended)
- People taking pegloticase, with whom the label says not to start or continue allopurinol
Pregnancy & breastfeeding
Pregnancy: the allopurinol label says that, based on animal findings, it may cause fetal harm, and that allopurinol and oxypurinol cross the placenta. Limited published human data (about 50 pregnancies) do not show a clear pattern of birth defects, although 2 infants with major malformations were reported. Anyone pregnant or planning pregnancy should discuss this with their doctor. Breastfeeding: the label says allopurinol and oxypurinol are present in human milk and, because of the potential for serious adverse reactions in a breastfed child, advises women not to breastfeed during treatment and for one week after the last dose.
Interactions
Allopurinol blocks xanthine oxidase, which breaks down azathioprine and mercaptopurine, so their levels and toxicity rise and can cause dangerous bone marrow suppression. The allopurinol label says that with 300 to 600 mg of allopurinol a day, the azathioprine or mercaptopurine dose needs to be cut to about one-third to one-quarter of usual. They should be combined only when the prescriber managing the azathioprine has planned it, with close blood count checks.
The label says allopurinol may blunt the rise in uric acid levels during pegloticase treatment and increase the risk of pegloticase-related anaphylaxis in people whose uric acid rises above 6 mg/dL, and that allopurinol should be stopped and not started during pegloticase treatment. Your rheumatologist manages this.
The label says these may raise the risk of skin rash with allopurinol, which may be severe, and that the thiazide risk is higher with reduced kidney function. Tell your prescriber you take allopurinol before an antibiotic or water pill is started, and report any rash right away.
The label says allopurinol may slow the breakdown of warfarin and strengthen its blood-thinning effect, and recommends checking the INR often when allopurinol is added. Make sure the clinic managing your warfarin knows.
The label says drowsiness, somnolence and dizziness have been reported with allopurinol and that its central nervous system depressant effects may be additive to those of alcohol. It advises against driving or using machinery when starting allopurinol or raising the dose, until you know how it affects you. No study has tested the combination.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (2)
+ azathioprine
criticalAllopurinol blocks one of the two enzymes that normally clear azathioprine from the body, so the same azathioprine dose becomes far more potent. The result is a well-documented and potentially fatal interaction.
+ alcohol
lowThe allopurinol label says drowsiness, somnolence and dizziness have been reported in patients taking it, and that its central nervous system depressant effects may be additive to those of alcohol. The caution is about alertness, mainly when starting allopurinol or raising the dose. No study has tested the combination.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I take azathioprine with allopurinol?⌄
Only if the prescriber managing your azathioprine has planned it. This page rates the pair critical: allopurinol blocks the enzyme that breaks down azathioprine, and the label says the azathioprine dose must be cut to about one-third to one-quarter of usual, with close blood count monitoring. The same applies to mercaptopurine.
Can I drink alcohol while taking allopurinol?⌄
The allopurinol label says it can cause drowsiness or dizziness, that its effects on the nervous system may add to those of alcohol and other sedating substances, and that you should not drive or use dangerous machinery when starting or raising the dose until you know how it affects you. Ask your doctor or pharmacist how much, if any, is reasonable for you.
Why did my gout flares get worse when I started allopurinol?⌄
The label explains that falling uric acid moves urate out of tissue deposits, which can trigger flares early on, and that control can take several months. It recommends a flare-preventing medicine at the start and says to keep taking allopurinol during a flare. Talk to your prescriber about flare prevention.
Should I take allopurinol with food?⌄
The label says it is generally better tolerated after meals, and to drink enough fluid to pass at least 2 liters of urine a day to help prevent kidney stones.
What should I do if I get a rash on allopurinol?⌄
The label says to stop allopurinol right away and seek medical attention promptly at the first sign of a rash, because rare reactions such as Stevens-Johnson syndrome can be serious or fatal. Contact your doctor or pharmacist the same day.
References by claim
lowering blood uric acid in gout
Seth et al., 2014 · PMC (2014) link
preventing heart attacks and strokes in heart disease without gout (not an approved use)
Mackenzie et al., 2022 · PubMed (2022) link
slowing chronic kidney disease without gout (not an approved use)
Badve et al., 2020 · PubMed (2020) link
Safety
Allopurinol tablets prescribing information · DailyMed (FDA label) link
Interaction: Azathioprine (and mercaptopurine)
Imuran (azathioprine) prescribing information · DailyMed (FDA label) link
Track Allopurinol with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
